Strepsils

Strepsils is a British over-the-counter throat-lozenge brand associated with relief of discomfort caused by minor mouth and throat infections. The brand originated within Boots Healthcare: it was first introduced as a mouthwash in 1950, followed by the launch of Strepsils throat lozenges in 1958. Its long-running identity is built around slowly dissolving tablets intended to deliver active ingredients locally in the mouth and throat while also providing flavor and soothing effects. The standard Strepsils formulation is based on the antiseptic combination of amylmetacresol and 2,4-dichlorobenzyl alcohol. Some variants add ingredients such as vitamin C or menthol, while other products use different active substances for more specialized relief. Strepsils Extra, for example, uses hexylresorcinol rather than the standard active-ingredient combination. In certain markets, Strepsils Plus products combine the antiseptic ingredients with lidocaine, a local anesthetic. A menthol-containing formulation is also sold for sore-throat and nasal discomfort in some markets. Formulations, names, indications, labeling, and regulatory status vary by country. The brand became part of Reckitt Benckiser, now Reckitt, when the company acquired Boots Healthcare brands in 2006. That transaction moved Strepsils from a Boots-associated healthcare portfolio into the global consumer-health platform of one of the world's largest branded health and hygiene companies. Reckitt's portfolio has enabled Strepsils to remain distributed across numerous national markets, although local brand architecture is not uniform. In Italy, comparable products are sold under the Benagol name; in Germany they have been marketed under Dobendan or Dobensana, and in Norway under Repsil. In North America, related products are sold under the Cēpacol brand. These market-specific names reflect regulatory, commercial, and historical differences rather than a single globally identical product range. Strepsils is positioned as an accessible, mass-market nonprescription healthcare brand. Its core promise is temporary symptomatic relief rather than treatment of the underlying cause of an infection. The brand's packaging and product variants commonly emphasize flavor, cooling sensations, antiseptic ingredients, anesthetic effects, or added vitamin C. The name is derived from Streptococcus, a group of bacteria associated with some types of sore throat, although the presence of an antiseptic ingredient should not be interpreted as proof that a product shortens or reduces the severity of every throat infection. The portfolio has also included stronger or differently formulated products. A product formerly marketed as Strepsils Intensive was subsequently marketed under the Strepfen name and contains flurbiprofen 8.75 mg. This illustrates the distinction between the core Strepsils lozenge range and products using other active pharmaceutical ingredients. Across markets, recommended dosing and safety instructions are determined by the relevant national label; the referenced standard guidance describes adult use at one tablet every two to three hours. Strepsils therefore combines a consistent heritage and recognizable brand name with a locally adapted range of regulated over-the-counter medicines.

Strepsils began within Boots Healthcare and was first introduced in 1950 as a mouthwash. The brand's defining throat-lozenge format followed in 1958. Since then, Strepsils has been associated primarily with dissolving tablets intended to ease sore-throat and mouth discomfort. The original and widely recognized formulations use amylmetacresol and 2,4-dichlorobenzyl alcohol, mild antiseptic ingredients used in products labeled for symptomatic relief. Some formulations also include flavoring or sensory ingredients such as menthol, while others add vitamin C. The product family expanded through differentiated formulations. Strepsils Extra uses hexylresorcinol as its active ingredient. Strepsils Plus products available in selected countries combine antiseptic ingredients with lidocaine, providing a local-anesthetic component. A vitamin-C formulation, Strepsils Vitamin C-100, combines the standard active ingredients with 100 mg of vitamin C per lozenge according to the referenced product description. Products and indications differ between jurisdictions because throat lozenges are regulated healthcare products and local labeling determines permitted claims, ingredients, strength, and dosing. Strepsils changed corporate ownership in 2006, when Reckitt Benckiser acquired Boots Healthcare brands. The acquisition integrated the brand into Reckitt's international consumer-health portfolio. Reckitt continues to manufacture and market Strepsils-associated products, while the brand's local presentation varies considerably. In Italy, related products are sold as Benagol; in Germany, as Dobendan or Dobensana, with the combined Dobendan Strepsils name used during part of the 2009–2013 period. In Norway, products have been sold under Repsil, and in North America under Cēpacol. Australia, Argentina, and Hungary have offered Strepsils Plus products with lidocaine, while France and Spain have offered lidocaine products under the Strepsils Lidocaine name. The range has also been separated from products using other anti-inflammatory or anesthetic ingredients. The product once marketed as Strepsils Intensive was later marketed under the Strepfen brand and contains flurbiprofen 8.75 mg. This naming change reflects portfolio differentiation rather than the disappearance of stronger sore-throat products from the wider Reckitt range. Strepsils' name refers to Streptococcus, bacteria associated with some sore-throat conditions. The brand's antiseptic ingredients may help address certain microorganisms locally, but product information notes that research has not established that the presence of an antibacterial agent necessarily reduces the duration or severity of an infection. The brand is therefore best understood as an over-the-counter symptomatic-relief line, not as a substitute for diagnosis or treatment of serious or persistent illness. Its continuing international presence rests on a combination of long heritage, recognizable packaging and flavors, multiple active-ingredient options, and adaptation to national healthcare markets.

1. 2013German co-branding period ended

   The Dobendan Strepsils name was used through 2013, after which German products were associated with Dobendan or Dobensana.

   Source
2. 2009Dobendan Strepsils naming used in Germany

   German market products were marketed under the Dobendan Strepsils name during the period beginning in 2009.

   Source
3. 2006Acquired by Reckitt Benckiser

   The brand transferred to Reckitt Benckiser as part of its acquisition of Boots Healthcare brands.

   Source
4. 1958Throat lozenges introduced

   Strepsils throat lozenges entered production and became the brand's principal product format.

   Source
5. 1950Initial introduction as a mouthwash

   Strepsils was introduced by Boots Healthcare as a mouthwash, establishing the brand's early association with mouth and throat care.

   Source

Mass-market, nonprescription consumer-health brand focused on temporary symptomatic relief of sore-throat and mouth discomfort through flavored dissolving lozenges and market-specific pharmaceutical formulations.

• Original StrepsilsAntiseptic throat lozenge1958

  The core Strepsils line uses amylmetacresol and 2,4-dichlorobenzyl alcohol as its principal active ingredients. It is designed to dissolve slowly in the mouth and provide temporary relief from sore-throat and mouth discomfort. Flavor and inactive ingredients vary by market and product presentation.

• Strepsils ExtraEnhanced throat lozenge

  Strepsils Extra is a variant using hexylresorcinol as its active ingredient rather than the standard amylmetacresol and 2,4-dichlorobenzyl alcohol combination. Its availability, labeling, and permitted claims depend on the country in which it is sold.

• Strepsils PlusLocal-anesthetic throat lozenge

  Available in markets including Australia, Argentina, and Hungary, Strepsils Plus combines the antiseptic ingredients found in original Strepsils with lidocaine. The lidocaine component provides a local-anesthetic effect, while national product information governs directions and restrictions.

• Strepsils LidocaineLocal-anesthetic throat lozenge

  In France and Spain, lidocaine-containing Strepsils products have been marketed under the Strepsils Lidocaine name. They represent a market-specific version of the brand's anesthetic throat-relief offering.

• Strepsils Vitamin C-100Vitamin-enriched throat lozenge

  This variant adds vitamin C to the standard Strepsils active-ingredient combination. The referenced formulation contains 100 mg of vitamin C per lozenge, alongside amylmetacresol and 2,4-dichlorobenzyl alcohol.

• Strepsils Intensive / StrepfenAnti-inflammatory sore-throat product

  The product formerly marketed as Strepsils Intensive was subsequently marketed under the Strepfen brand. It uses flurbiprofen 8.75 mg, distinguishing it pharmacologically from the core antiseptic Strepsils lozenge range.

• 2006Transfer of Strepsils to Reckitt BenckiserM&A

  Strepsils was among the Boots Healthcare brands acquired by Reckitt Benckiser.

  What changed. The brand was incorporated into Reckitt Benckiser's international consumer-health portfolio.

  Aftermath. Strepsils continued as a global brand within the company now known as Reckitt, with market-specific formulations and names.

  Source
• Separation of the Intensive product under the Strepfen nameStrategy

  The flurbiprofen-based stronger sore-throat product differed from the standard Strepsils antiseptic formulations.

  What changed. The product formerly marketed as Strepsils Intensive was marketed under the Strepfen brand.

  Aftermath. The change distinguished the anti-inflammatory product from the main Strepsils lozenge family.

  Source

• 2006Boots Healthcare brands, including Strepsils, acquired by Reckitt Benckiser

  Strepsils became part of Reckitt Benckiser's branded healthcare portfolio through the acquisition of Boots Healthcare brands.

  M&A
  Source
• Strepsils Intensive marketed under the Strepfen brand

  The stronger flurbiprofen-based product formerly associated with the Strepsils Intensive name was subsequently marketed as Strepfen.

  Product generation
  Source

1. Strepsils